Kovaltry Safe, Effective for Children With Hemophilia A in Real-world Study

Kovaltry Safe, Effective for Children With Hemophilia A in Real-world Study

285050

Kovaltry Safe, Effective for Children With Hemophilia A in Real-world Study

Kovaltry (octocog alfa) is effective and safe as a preventive treatment for children with hemophilia A, a European real-world study reports. The study, “Real-world evidence on Kovaltry (81-8973) in children with moderate or severe hemophilia A in Europe: a nested cohort analysis,” was published in the Orphanet Journal of Rare Diseases. In hemophilia A, a mutation in the gene coding for clotting factor VIII (FVIII) makes patients prone to bleeds in muscles and joints. To…

You must be logged in to read/download the full post.